Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
1 Visualizzazioni
• 07/14/23
0
0
Incorporare
administrator
Iscritti
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti